Literature DB >> 31774001

Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States.

Mary Clare Masters1, Karen M Krueger1, Janna L Williams1, Lindsay Morrison1, Susan E Cohn1.   

Abstract

Introduction: Modern antiretroviral therapy (ART) has revolutionized HIV treatment. ART regimens are now highly efficacious, well-tolerated, safe, often with one multi-drug pill, once-daily regimens available. However, clinical challenges persist in managing ART in persons with HIV (PWH), such as drug-drug interactions, side effects, pregnancy, co-morbidities, and adherence.Areas Covered: In this review, we discuss the ongoing challenges of ART for adults in the United States. We review the difficulties of initiating ART and maintaining therapy throughout adulthood and discuss new agents and strategies under investigation to address these issues. A PubMed search was utilized to identify relevant publications and guidelines through July 2019.Expert Opinion: Challenges persist in initiation and maintenance of ART. An individual's coexisting medical, social and personal factors must be considered in selecting and continuing ART to ensure safety, tolerability, and efficacy throughout adulthood. Continued development of new therapeutics and novel approaches to ART, such as long acting drugs or dual therapy, are needed to respond to many of these challenges. In addition, future research must address therapeutic disparities for populations historically underrepresented in clinical trials, including women, people aging with HIV, and those with complex comorbidities.

Entities:  

Keywords:  AIDS; Adults; Antiretroviral therapy; HIV; aging; drug-drug interactions; non-AIDS-related comorbidities; women

Mesh:

Substances:

Year:  2019        PMID: 31774001      PMCID: PMC7073258          DOI: 10.1080/17512433.2019.1698946

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN: 1751-2433            Impact factor:   5.045


  174 in total

1.  Integrase strand transfer inhibitor-associated diabetes mellitus: A case report.

Authors:  Peter S Fong; Devon M Flynn; Christopher D Evans; P Todd Korthuis
Journal:  Int J STD AIDS       Date:  2016-10-12       Impact factor: 1.359

2.  First reported use of elvitegravir and cobicistat during pregnancy.

Authors:  Stein Schalkwijk; Angela Colbers; Deborah Konopnicki; Rick Greupink; Frans G M Russel; David Burger
Journal:  AIDS       Date:  2016-03-13       Impact factor: 4.177

3.  Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.

Authors:  Babafemi O Taiwo; Vincent C Marconi; Baiba Berzins; Carlee B Moser; Amesika N Nyaku; Carl J Fichtenbaum; Constance A Benson; Timothy Wilkin; Susan L Koletar; Jonathan Colasanti; Edward P Acosta; Jonathan Z Li; Paul E Sax
Journal:  Clin Infect Dis       Date:  2018-05-17       Impact factor: 9.079

4.  Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

Authors:  Jean-Michel Molina; Kathleen Squires; Paul E Sax; Pedro Cahn; Johan Lombaard; Edwin DeJesus; Ming-Tain Lai; Xia Xu; Anthony Rodgers; Lisa Lupinacci; Sushma Kumar; Peter Sklar; Bach-Yen Nguyen; George J Hanna; Carey Hwang
Journal:  Lancet HIV       Date:  2018-03-25       Impact factor: 12.767

Review 5.  Recommendations for Managing Drug-Drug Interactions with Statins and HIV Medications.

Authors:  Barbara S Wiggins; Donald G Lamprecht; Robert L Page; Joseph J Saseen
Journal:  Am J Cardiovasc Drugs       Date:  2017-10       Impact factor: 3.571

6.  Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis.

Authors:  David R Boulware; David B Meya; Conrad Muzoora; Melissa A Rolfes; Katherine Huppler Hullsiek; Abdu Musubire; Kabanda Taseera; Henry W Nabeta; Charlotte Schutz; Darlisha A Williams; Radha Rajasingham; Joshua Rhein; Friedrich Thienemann; Melanie W Lo; Kirsten Nielsen; Tracy L Bergemann; Andrew Kambugu; Yukari C Manabe; Edward N Janoff; Paul R Bohjanen; Graeme Meintjes
Journal:  N Engl J Med       Date:  2014-06-26       Impact factor: 91.245

7.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

8.  Weight Gain Associated With Integrase Stand Transfer Inhibitor Use in Women.

Authors:  Anne Marie Kerchberger; Anandi N Sheth; Christine D Angert; C Christina Mehta; Nathan A Summers; Ighovwerha Ofotokun; Deborah Gustafson; Sheri D Weiser; Anjali Sharma; Adaora A Adimora; Audrey L French; Michael Augenbraun; Jennifer Cocohoba; Seble Kassaye; Hector Bolivar; Usha Govindarajulu; Deborah Konkle-Parker; Elizabeth T Golub; Cecile D Lahiri
Journal:  Clin Infect Dis       Date:  2020-07-27       Impact factor: 9.079

9.  Implementation of a Rapid Entry Program Decreases Time to Viral Suppression Among Vulnerable Persons Living With HIV in the Southern United States.

Authors:  Jonathan Colasanti; Jeri Sumitani; C Christina Mehta; Yiran Zhang; Minh Ly Nguyen; Carlos Del Rio; Wendy S Armstrong
Journal:  Open Forum Infect Dis       Date:  2018-06-28       Impact factor: 3.835

10.  Prevalence and trends of polypharmacy among HIV-positive and -negative men in the Multicenter AIDS Cohort Study from 2004 to 2016.

Authors:  Deanna Ware; Frank J Palella; Kara W Chew; M Reuel Friedman; Gypsyamber D'Souza; Ken Ho; Michael Plankey
Journal:  PLoS One       Date:  2018-09-11       Impact factor: 3.752

View more
  6 in total

1.  Perceptions of HIV Virologic Control Strategies Among Younger and Older Age Groups of People Living with HIV in the United States: A Cross-Sectional Survey.

Authors:  Parya Saberi; Shadi Eskaf; John Sauceda; David Evans; Karine Dubé
Journal:  AIDS Res Hum Retroviruses       Date:  2020-05-27       Impact factor: 2.205

2.  Perceptions of Risks and Benefits of Participating in HIV Cure-Related Research Among Diverse Young Adults Living with HIV in the United States: Qualitative Research Findings.

Authors:  Parya Saberi; Chadwick K Campbell; John A Sauceda; Samuel Ndukwe; Karine Dubé
Journal:  AIDS Res Hum Retroviruses       Date:  2022-06-28       Impact factor: 1.723

3.  The Association Of HIV With Health Care Spending And Use Among Medicare Beneficiaries.

Authors:  José F Figueroa; Ingrid T Katz; Emily P Hyle; Kathryn E Horneffer; Kavya Nambiar; Jessica Phelan; E John Orav; Ashish K Jha
Journal:  Health Aff (Millwood)       Date:  2022-04       Impact factor: 9.048

4.  A New Approach to Developing Long-Acting Injectable Formulations of Anti-HIV Drugs: Poly(Ethylene Phosphoric Acid) Block Copolymers Increase the Efficiency of Tenofovir against HIV-1 in MT-4 Cells.

Authors:  Ilya Nifant'ev; Andrei Siniavin; Eduard Karamov; Maxim Kosarev; Sergey Kovalchuk; Ali Turgiev; Sergey Nametkin; Vladimir Bagrov; Alexander Tavtorkin; Pavel Ivchenko
Journal:  Int J Mol Sci       Date:  2020-12-30       Impact factor: 5.923

5.  Ethical and practical considerations for HIV cure-related research at the end-of-life: a qualitative interview and focus group study in the United States.

Authors:  John Kanazawa; Sara Gianella; Susanna Concha-Garcia; Jeff Taylor; Andy Kaytes; Christopher Christensen; Hursch Patel; Samuel Ndukwe; Stephen A Rawlings; Steven Hendrickx; Susan Little; Brandon Brown; Davey Smith; Karine Dubé
Journal:  BMC Med Ethics       Date:  2022-01-11       Impact factor: 2.652

Review 6.  The LAIs Are Coming! Implementation Science Considerations for Long-Acting Injectable Antiretroviral Therapy in the United States: A Scoping Review.

Authors:  John T Kanazawa; Parya Saberi; John A Sauceda; Karine Dubé
Journal:  AIDS Res Hum Retroviruses       Date:  2020-12-07       Impact factor: 2.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.